Loading…
Puma Biotechnology, Inc. is projected to rise to $9.97 by 2027, a +36% move from its current price of $7.31. PBYI is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $7.18 | $7.32 | $7.45 | +0.07% |
| May 30 | $7.13 | $7.32 | $7.52 | +0.14% |
| May 31 | $7.09 | $7.33 | $7.57 | +0.21% |
| Jun 1 | $7.06 | $7.33 | $7.61 | +0.29% |
| Jun 2 | $7.04 | $7.34 | $7.65 | +0.36% |
| Jun 3 | $7.01 | $7.34 | $7.68 | +0.43% |
| Jun 4 | $6.99 | $7.35 | $7.72 | +0.50% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $6.99 | $7.35 | $7.72 | +0.50% |
| Week 2 | $6.89 | $7.38 | $7.92 | +1.00% |
| Week 3 | $6.81 | $7.42 | $8.08 | +1.51% |
| Week 4 | $6.76 | $7.46 | $8.23 | +2.01% |
| Week 5 | $6.71 | $7.49 | $8.37 | +2.52% |
| Week 6 | $6.67 | $7.53 | $8.50 | +3.04% |
| Week 7 | $6.64 | $7.57 | $8.63 | +3.55% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products to enhance cancer care in the United States and internationally.
It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.
The company also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. Puma Biotechnology was founded in 2010 and is headquartered in Los Angeles, California.
Puma Biotechnology, Inc. trades under the symbol PBYI and holds a market capitalization of $360.37M, ranking 3330 by market position.
The current price is $7.08.
The price outlook, based on the provided multi-year forecast, shows potential upside across the horizon, with average prices trending higher in later years. Forecasts indicate notable upside by 2040 and 2050, with average prices of $58.01 in 2040 and $144.23 in 2050.
A major floor 22.0% below — a decisive break under it would weaken the trend.
The nearest floor, 6.8% below — buyers have tended to step in here.
The nearest ceiling, 3.1% above — a clean break opens room to run.
A major ceiling 8.8% above — clearing it would confirm fresh momentum.
Key PBYI support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PBYI market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $7.14 | Buy | $7.17 | Buy |
| MA 10 | $7.06 | Buy | $7.14 | Buy |
| MA 20 | $7.22 | Buy | $7.17 | Buy |
| MA 50 | $7.05 | Buy | $7.05 | Buy |
| MA 100 | $6.78 | Buy | $6.69 | Buy |
| MA 200 | $5.97 | Buy | $6.00 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 55.00 | Neutral |
| Stoch RSI (14) | 91.03 | Sell |
| CCI (20) | 31.11 | Neutral |
| Williams %R (14) | -26.47 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | -2.40 | Sell |
| Bollinger %B (20,2) | 0.60 | Neutral |
| Stochastic %K (14) | 73.53 | Neutral |
| TRIX (15) | -0.03 | Sell |
| Awesome (5,34) | -0.19 | Sell |
| Ultimate (7,14,28) | 67.33 | Neutral |
| Momentum (10) | 0.23 | Buy |
| Aroon Osc (25) | -60.00 | Sell |
| Hull MA (9) | 7.27 | Buy |
| ADX (14) | 13.24 | Neutral |
| ATR (14) | 0.12 | Info |
The current technical picture is bullish in tone. RSI(14) is 50 and the near-term trend is supported by a SMA50 of $7.00 against a SMA200 of $5.93.
Key levels to watch include a support at $6.81 and a resistance at $7.57, with the 30-day price range quoted from $6.24 to $8.03. Annualized volatility stands at 40%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $5.70 | $7.31 | $10.66 | 0% | Neutral | |
| $8.15 | $9.97 | $12.78 | +36% | Bullish | |
| $10.22 | $12.73 | $16.74 | +74% | Bullish | |
| $13.05 | $16.52 | $22.17 | +126% | Bullish | |
| $15.75 | $20.20 | $27.59 | +176% | Bullish | |
| $18.34 | $23.80 | $33.02 | +226% | Bullish | |
| $19.23 | $25.23 | $35.49 | +245% | Bullish | |
| $21.74 | $28.82 | $41.06 | +294% | Bullish | |
| $24.93 | $33.38 | $48.13 | +357% | Bullish | |
| $26.41 | $35.69 | $52.02 | +388% | Bullish | |
| $44.93 | $63.33 | $96.70 | +766% | Bullish | |
| $105.10 | $158.84 | $259.91 | +20.7x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $5.70 | $7.31 | $8.56 | +0.00% |
| June 2026 | $6.46 | $7.54 | $8.97 | +3.16% |
| July 2026 | $6.65 | $7.80 | $9.36 | +3.44% |
| August 2026 | $6.66 | $7.84 | $9.48 | +0.55% |
| September 2026 | $6.80 | $8.05 | $9.79 | +2.58% |
| October 2026 | $7.15 | $8.49 | $10.38 | +5.47% |
| November 2026 | $7.28 | $8.67 | $10.65 | +2.13% |
| December 2026 | $7.24 | $8.64 | $10.66 | -0.33% |
Click any year to see its month-by-month PBYI forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, PBYI is projected to trade between $5.70 and $10.66, averaging $7.31 — a potential gain of 0% from today's $7.31. A consolidation phase looks the most probable path here.
Puma Biotechnology, Inc.'s 2027 outlook centres on $9.97, within a $8.15 to $12.78 range. That is up +36% on the projected 2026 average. That marks a +36% change versus current levels. Momentum favours further upside here.
By 2028, PBYI could reach as high as $16.74, with a base case around $12.73 and support toward $10.22 — roughly +74% from $7.31. Buyers look set to stay in control over this stretch.
Expect PBYI to range from $13.05 to $22.17 through 2029. The $16.52 average target implies a +126% move from current prices. That is up +30% on the projected 2028 average. Momentum favours further upside here.
The PBYI price prediction for 2030 points to an average of $20.20 (low $15.75, high $27.59) — a potential gain of +176% on today's $7.31. Buyers look set to stay in control over this stretch.
In 2031, PBYI is projected to trade between $18.34 and $33.02, averaging $23.80 — a potential gain of +226% from today's $7.31. That is up +18% on the projected 2030 average. Momentum favours further upside here.
Puma Biotechnology, Inc.'s 2032 outlook centres on $25.23, within a $19.23 to $35.49 range. That is up +6% on the projected 2031 average. That marks a +245% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, PBYI could reach as high as $41.06, with a base case around $28.82 and support toward $21.74 — roughly +294% from $7.31. Momentum favours further upside here.
Expect PBYI to range from $24.93 to $48.13 through 2034. The $33.38 average target implies a +357% move from current prices. That is up +16% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The PBYI price prediction for 2035 points to an average of $35.69 (low $26.41, high $52.02) — a potential gain of +388% on today's $7.31. Momentum favours further upside here.
In 2040, PBYI is projected to trade between $44.93 and $96.70, averaging $63.33 — a potential gain of +766% from today's $7.31. That is up +77% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Puma Biotechnology, Inc.'s 2050 outlook centres on $158.84, within a $105.10 to $259.91 range. That is up +151% on the projected 2040 average. That marks a +20.7x change versus current levels. Momentum favours further upside here.
Investing $1,000 in PBYI today (≈ 136.798906 PBYI) could be worth
$21,729.47
+$20,729.47 (+2073%) by 2050 · US Dollar
Based on the average projected PBYI price of $158.84 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PBYIwould be worth at today's price.
$1,000 invested in PBYI on May 27, 2025 (≈ 290.69767 PBYI) would be worth
$2,125
+$1,125 (+112.5%) today · 2.12× · US Dollar
Based on a PBYI entry price of $3.44 vs. today's $7.31.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $6.99 | $1,045.78 | +4.6% |
| 1 month ago | $7.51 | $973.37 | -2.7% |
| 3 months ago | $7.6 | $961.84 | -3.8% |
| 6 months ago | $5.05 | $1,447.52 | +44.8% |
| 1 year ago | $3.44 | $2,125 | +112.5% |
| All time (5.0y) ago | $10.71 | $682.54 | -31.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PBYI forecast.
Our base-case forecast reaches $15.00 around 2029.
Implied market cap at $15.00: $763.49M
The year-by-year forecast shows 2026 with a min of $5.70, an avg of $7.08, and a max of $10.31, with ROI 0 and sentiment Neutral.
For 2027 the min is $7.84, the avg is $9.61, the max is $12.33, with ROI 35.7 and sentiment Bullish. 2028 adds momentum at a min of $9.70, avg $12.10, max $15.95, ROI 71 and sentiment Bullish.
From 2029 through 2035 the trajectory continues higher: 2029 min $12.39, avg $15.70, max $21.12 (ROI 121.8, Bullish); 2030 min $14.90, avg $19.14, max $26.21 (ROI 170.3); 2031 min $17.14, avg $22.29, max $31.00 (ROI 214.8); 2032 min $18.00, avg $23.68, max $33.40 (ROI 234.4); 2033 min $20.33, avg $27.03, max $38.62 (ROI 281.7); 2034 min $23.05, avg $30.94, max $44.75 (ROI 337); 2035 min $24.39, avg $33.05, max $48.33 (ROI 366.9).
By 2040 the forecast shows min $41.01, avg $58.01, max $88.91 with ROI 719.3 and sentiment Bullish. By 2050 min $94.96, avg $144.23, max $237.07 with ROI 1937.2 and sentiment Bullish.
Tap a question to reveal the answer.
The 2030 forecast lists a min of $14.90, an avg of $19.14, and a max of $26.21, with ROI 170.3 and sentiment Bullish.
The forecast shows a bullish trajectory across multiple years, with substantial upside by 2040 and 2050 (e.g., avg $58.01 in 2040 and avg $144.23 in 2050), though these are estimates and not guarantees.
Yes. The 2040 forecast max is $88.91, which would exceed $50; earlier years peak below $50 (e.g., 2035 max $48.33).
Current price is $7.08 and market capitalization is $360.37M.
The near-term setup is bullish with RSI(14) at 50, SMA50 at $7.00, SMA200 at $5.93, support at $6.81 and resistance at $7.57, and a 30-day range of $6.24 to $8.03.
Puma Biotechnology, Inc. Community Discussion
0Share your Puma Biotechnology, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.